Fennec Pharmaceuticals Inc. announced a non-brokered offering of common shares in Canada at a price of US$7.50 per share, with aggregate gross proceeds of up to US$5,025,000. The offering is expected to close on November 17, 2025, subject to necessary approvals, including from the Toronto Stock Exchange. The common shares will be offered and sold solely in Canada, with no hold period under Canadian securities laws. Prospective investors can access the offering document on the Company’s website.

Fennec Pharmaceuticals is focused on fighting ototoxicity in cancer patients receiving cisplatin-based chemotherapy. PEDMARK® is commercialized to reduce the risk of platinum-induced ototoxicity and has received approvals in the U.S., Europe, and the U.K. The company has entered into a licensing agreement for commercialization in Europe, the U.K., Australia, and New Zealand. Fennec holds patents protecting PEDMARK® until 2039. Forward-looking statements caution about risks and uncertainties related to the offering and the Company’s business operations.

Read more at GlobeNewswire: Fennec Pharmaceuticals Announces Private Offering of Common